|
Share this Article:
Interest in CyGene DNA Consumer Testing Products Increases After Recent Media CoverageCategory: Press Releases | Permalink Published: Wednesday, May 12, 2010 CORAL SPRINGS, Fla., May 12, 2010 (GlobeNewswire via COMTEX) -- CyGene Laboratories Inc. (Pink Sheets:CYGE) today announced that it has experienced unprecedented levels of interest and requests for information following recent media coverage of Walgreens' (WAG 36.57, +0.40, +1.11%) decision to offer genetic testing kits supplied by Pathway Genomics in certain of their retail stores. "Our phone has been ringing off the hook," said Martin Munzer, CEO of CyGene Laboratories. "Since the news broke, we have been inundated with calls and emails. People are suddenly very interested in the whole world of at-home genetic testing. While we do not comment on specific competitors and their products, it's important that we point out our own distinctive competencies and make clear the benefits of our technology and testing methodology as well as our position regarding the key issues affecting our industry." Looking to address the heightened interest in CyGene's products, Mr. Munzer issued the following statement: "CyGene has been offering direct-to-consumer DNA testing since 2004. Our products are purely predictive, meaning they are not diagnostic tests. We have designed and filed patents on methods and procedures that provide an ethical and economic way of making genetic information available for the benefit and private use of our clients. Most importantly, our testing is anonymous, not just confidential -- a critical factor when considering all the information that can be harvested from the human genome. The results of our tests are actionable, but in a positive way: We do not scare consumers into taking radical, irreversible measures to reduce a possible risk based on inconclusive or partial information. "There are many issues related to this 'brave new world' of genomics that yet need to be resolved, such as the patenting of genes. Many companies have been issued patents and actually 'own' some genes, as in the case of the BRCA1 and BRCA2 genes, which may increase the risk of developing breast cancer. By way of these rights, companies are denying access to the use of these genes to others for testing and even for the development of drugs to modify the function of the genes. As a result, in our opinion, some companies are overcharging the public for testing, while overstating the real value of their genetic markers. CyGene has been a staunch opponent of gene patenting. Our position on this issue is clear and a matter of public record as I have written letters for use by members of Congress sponsoring bills attempting to repeal the laws that permit the patenting of human or other genes." About CyGene Laboratories, Inc.CyGene Laboratories, Inc., based in Coral Springs, Fla., is a biotechnology company focused on introducing genetic predisposition and diagnostic testing into the general population. With five patents issued, CyGene's scientific expertise is in DNA analysis and diagnostic technologies. Incorporated in 1995, CyGene has been developing technology and introducing products that address the growing demand for genetic knowledge implementation and utilization. CyGene currently markets eight DNA predictive genetic test panels in accordance with its patent pending business model, sold direct to consumers and through physicians and other healthcare practitioners. CyGene's process offers customers access to the most updated science, guaranteeing their anonymity and keeping consumers on the cutting edge of genetic discoveries at the lowest possible price. The method allows customers who have purchased a previous genetic test panel a low cost upgrade to their genetic report as new genetic discoveries become available. For more information about CyGene Laboratories and its products, visit the Company's Web site at: Forward-Looking Statements: The statements made in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Additionally words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, when or whether the audits of our financial statements will be completed and audit opinions issued, due to unforeseen circumstances or unforeseen issues that may arise during the course of such audits. CyGene Laboratories Inc. has no duty and undertakes no obligation to update such statements. You should independently investigate and fully understand all risks before making investment decisions. Jump to Top
Share this Article:
CyGene Laboratories Forms New International Sales OrganizationCategory: Press Releases | Permalink Published: Wednesday, April 28, 2010 CORAL SPRINGS, Fla.--(GLOBE NEWSWIRE)--CyGene Laboratories Inc. (OTC: CYGE - News) today announced that it has formed an international sales organization that is tasked with rapidly expanding the number of sales channels for the company's multiple DNA test panels, which are marketed primarily to consumers. Heading this new organization is Rodolfo E. Gonzalez who has been named Director of Global Development. He will be based out of the company's Coral Springs corporate headquarters. Mr. Gonzalez was formerly the Executive Vice President of Sales and Marketing (Latin America) for a multi-national publicly-traded Fortune 500 company. He has extensive knowledge and experience in all aspects of channel development and sales management. "We are pleased to have someone like Rodolfo join our organization, "said Martin Munzer, the CEO of CyGene. "We have high expectations based on his background and proven track record of building revenues in high growth industries." Mr. Gonzalez said, "CyGene is uniquely positioned to bring the diagnostic and predictive benefits of genetic testing to the general population. I'm very excited to be a part of the CyGene team." Mr. Gonzalez will lead the company's effort to rapidly expand its sales channels globally and build a world class sales organization. Mr. Gonzalez has indicated that he expects to work closely with CyGene's existing channel partners. About CyGene Laboratories, Inc.CyGene Laboratories, Inc., based in Coral Springs, Fla., is a biotechnology company focused on introducing genetic predisposition and diagnostic testing into the general population. With five patents issued, CyGene's scientific expertise is in DNA analysis and diagnostic technologies. Incorporated in 1995, CyGene has been developing technology and introducing products that address the growing demand for genetic knowledge implementation and utilization. CyGene currently markets eight DNA predictive genetic test panels in accordance with its patent pending business model, sold direct to consumers and through physicians and other healthcare practitioners. CyGene's process offers customers access to the most updated science, guaranteeing their anonymity and keeping consumers on the cutting edge of genetic discoveries at the lowest possible price. The method allows customers who have purchased a previous genetic test panel a low cost upgrade to their genetic report as new genetic discoveries become available. For more information about CyGene Laboratories and its products, visit the Company's Web site at: Forward-Looking Statements: The statements made in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Additionally words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, when or whether the audits of our financial statements will be completed and audit opinions issued, due to unforeseen circumstances or unforeseen issues that may arise during the course of such audits. CyGene Laboratories Inc. has no duty and undertakes no obligation to update such statements. You should independently investigate and fully understand all risks before making investment decisions. Jump to Top
Share this Article:
Los Angeles Times asks CyGene President Martin Munzer to Weigh in on Jamaican Sprinter Usain BoltCategory: Media Room | Permalink Published: Friday, September 04, 2009 
CyGene Laboratories is recognized as the industry leading in athletic performance testing, helping everyone from professional athletes to weekend warriors achieve their optimal athletic goals. As a testament to the company's reputation, CyGene President Martin Munzer was recently quoted in a Los Angeles Times article weighing in on the athletic prowess of Jamaican sprinter Usain Bolt. At 6-feet-5, Bolt's un-sprinter-like build yet world record setting performances have challenged traditional thinking about what makes a good sprinter. Competing against shorter, stockier athletes, the laws of physics would suggest Bolt is at a distinct disadvantage when it comes to getting up to speed quickly, a necessity in sprints, and not losing steam toward the end as sprinters can be inclined to do. Experts in the field of exercise science pointed to Bolt's physical movements and whether or not he engaged in "dorsiflexion" the practice of flexing the foot toward the shin. But even those experts disagreed on whether dorsiflexion was good or bad for a sprinter and the Times article raised the question of whether Bolt carried the ACTN3 gene, sometimes referred to as the speed gene, which other elite athletes have been found to possess. "There's no question in my mind that he's going to have a convergence of certain genetics that contribute to his success," Munzer is quoted as saying. But Munzer is also quick to point out that genetics tell only part of the story. "You can affect the existing genes by switching them on and off through dietary or environment effects, like smoking." The Los Angeles Times article captures the essence of why personalized genetic testing is so important for athletes looking to understand how their bodies can work. Munzer goes on to say, "Just because you have a genetic profile it doesn't predestine you to anything." In other words, having the right genes for athletic success may be moot if the athlete a) doesn't know he possesses these genes and b) doesn't understand that diet and environmental influences affect the performance of these genes in the overall body. Usain Bolt is one of the fastest men alive despite his body-type, sending the message that there is more to athletic performance than height, weight and muscle composition. The athletic performance panels offered by CyGene Laboratories offer insight into some of those other factors and help athletes reach their peak performance goals. Jump to Top
Share this Article:
CyGene’s CEO To Speak At Russian Academy of Sciences Diagnostics ConferenceCategory: Press Releases | Permalink Published: Friday, August 28, 2009 CORAL SPRINGS, Fla.--(GLOBE NEWSWIRE)--CyGene Laboratories Inc. (OTC: CYGE - News) today announced that its CEO Martin Munzer, has been invited to speak at a Russian Academy of Sciences diagnostics symposium in Vladivostok on September 8. The company recently announced that its direct-to-consumer predictive genetic products have been introduced in the Russian Federation by its exclusive licensee CyGene Russia, LLC. The CyGene products are the first predictive DNA tests for the Russian market. "I'm very pleased and excited about this speaking opportunity." Munzer said. "The Russian scientific community is keenly interested in using genetic science to improve the health of their citizens, and the Russian Federation represents a wonderful market opportunity for CyGene's products and technologies." He added, "My presentation will encompass CyGene's unique approach to implementing predictive genetic knowledge today and also include CyGene's ability to significantly improve infectious disease diagnostics using our patented Haystack Processing techniques." "Scientists and businessmen must work together," said Professor Iosif Piven, Vice President of the Far Eastern Public Academy of Sciences in his invitation to CyGene. "And we have to accelerate such a cooperation, since time is money, and Russia has a broad market for scientifically developed products and services." About CyGene Laboratories Inc.CyGene Laboratories Inc., based in Coral Springs, Fla., is a biotechnology company focused on introducing genetic predisposition and diagnostic testing into the general population. With five patents issued, CyGene's scientific expertise is in DNA analysis and diagnostic technologies. Incorporated in 1995, CyGene has been developing technology and introducing products that address the growing demand for genetic knowledge implementation and utilization. CyGene currently markets eight DNA predictive genetic test panels in accordance with its patent pending business model, sold direct to consumers and through physicians and other healthcare practitioners. CyGene's process offers customers access to the most updated science, guaranteeing their anonymity and keeping consumers on the cutting edge of genetic discoveries at the lowest possible price. The method also allows customers who have purchased a previous genetic test panel a low cost upgrade to their genetic report as new genetic discoveries become available. For more information about CyGene Laboratories and its products, visit the Company's Web site at: Contact:
Jump to Top
Share this Article:
CyGene Laboratories Inc. New Customer-Focused WebsiteCategory: Press Releases | Permalink Published: Thursday, August 27, 2009 CORAL SPRINGS, Fla.--(GLOBE NEWSWIRE)--CyGene Laboratories Inc. (OTC: CYGE - News) today announced that it has launched a new Website, www.cygenedirect.com, where consumers can get information and order predictive genetic tests geared to informing consumers about specific options to help improve health, while maintaining anonymity. The consumer-friendly Website features easy online ordering of the company's products. The site also includes comprehensive personal assessment information and details about potential benefits of the products, as well as detailed consumer information about genetics and genetic testing. The site also features links to the company's blog and its social media sites. "People have a unique opportunity with CyGene to start learning about their personal genetics and how their genes may impact their lives. Generally, this will be their first brush with this exciting new field of science and our new Website can help them find out how genetic testing works, which kits are best for them, and how they can be used to improve overall quality of life and athletic performance," said Martin Munzer, president and CEO of CyGene. "And our new site makes it easier than ever for people to get the information and products they're looking for with guaranteed anonymity." The new creative direction of CyGeneDirect.com comes by way of Infinity Arts. "Our objective for CyGeneDirect.com was to re-invigorate the consumer website to be more compelling; easy to understand, navigate and relate to, while strategically improving visibility on the internet via search engines and online social mediums," said Michael Leahy, CEO for Infinity Arts. About CyGene Laboratories Inc.CyGene Laboratories Inc., based in Coral Springs, Fla., is a biotechnology company focused on introducing genetic predisposition and diagnostic testing into the general population. With five patents issued, CyGene's scientific expertise is in DNA analysis and diagnostic technologies. Incorporated in 1995, CyGene has been developing technology and introducing products that address the growing demand for genetic knowledge implementation and utilization. CyGene currently markets eight DNA predictive genetic test panels in accordance with its patent pending business model, sold direct to consumers and through physicians and other healthcare practitioners. CyGene's process offers customers access to the most updated science, guaranteeing their anonymity and keeping consumers on the cutting edge of genetic discoveries at the lowest possible price. The method also allows customers who have purchased a previous genetic test panel a low cost upgrade to their genetic report as new genetic discoveries become available. For more information about CyGene Laboratories and its products, visit the Company's Web site at: About Infinity Arts Interactive, LLCInfinity Arts, founded by Michael Leahy in 1999, specializes in results driven web design, web development and online marketing. Infinity Arts focus is based on strategically engaging consumers with invigorating brand and online marketing while cohesively interacting with search engines. To learn more about Infinity Arts visit: www.InfinityArts.com Contact:
Jump to Top Other Recent ArticlesDNA Decoded – Bicycling Magazine Highlights CyGene’s Athletic Performance Genetic Testing PanelsCategory: Media Room Published: Wednesday, August 12, 2009 CyGene Laboratories is the industry leader in athletic performance genetic testing, helping everyone from professional athletes to weekend warriors achieve their optimal athletic goals. Bicycling Magazine was so impressed with the company’s athletic performance testing products that the company is featured in the September, 2009 issue cover story, “DNA Decoded”. Jump to Top CyGene Shareholders Post Their Opinion on Pinnacle Digest’s Internet Stock ForumCategory: Press Releases Published: Monday, August 10, 2009 Pinnacle Digest has asked CyGene shareholders to share their thoughts about the company in Pinnacle Digest’s investor forum. Although CyGene has not actively promoted company stock, it is prone to significant price changes based on a few shares being bought or sold. Jump to Top CyGene Introduces Their New Alcohol-Dependence DNA AnalysisCategory: Press Releases Published: Thursday, August 06, 2009 CyGene introduces a new alcohol-dependence predictive genetic product that analyzes genes associated with increased risk for excessive alcohol consumption, substance abuse and some of the related complications with these behaviors. This test, as well as all other CyGene products can help improve people’s lives and are based on concrete scientific research. Jump to Top CyGene Introduces Predictive Genetic Products in RussiaCategory: Press Releases Published: Tuesday, August 04, 2009 CyGene Russia, Russia predictive genetic products, Russia DNA predictive genetic tests, first predictive DNA tests in Russia, Russia DNA genetic tests Jump to Top Hello and welcome, We've just launched our blog, stay tuned for great information and resources. Jump to Top CyGene’s Strokescan | Stroke, Cardiovascular & Kidney Disease Genetic TestCategory: Press Releases Published: Monday, July 21, 2008 CyGene’s Strokescan is a genetic screening test that identifies individuals that may be at risk and have family history of stroke, cardiovascular or kidney disease. StrokeScan also has the ability to save lives by discovering, recognizing and diagnosing Fabry disease accurately. With StrokeScan’s screening, carriers can have knowledge about their disease and treat it in a timely manner. Jump to Top CyGene Receives Shareholder Approval to Increase Common SharesCategory: Press Releases Published: Wednesday, February 27, 2008 CyGene’s shareholders approve the increase of common shares to 200,000,000 shares from 75,000,000. CyGene states that the increase will permit room for conversion of a significant amount of current debt into equity. |
Categories
CyGene Laboratories Receives CLIA Laboratory Registration. The State of Florida Agency for Health Care Administration has provided CyGene with a certificate that will allow its lab to perform clinical diagnostic testing. Learn More
RSS •
Investor Relations •
Contact •
Sitemap
About This Page: Learn more about CyGene and dna testing with our DNA blog. CyGene’s DNA testing blog offers up to date DNA testing and genetic testing information. For the latest on DNA testing, visit our Genetic Testing Blog.
